Results 51 to 60 of about 8,068 (200)
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
The inclusion body myositis is an inflammatory myopathy that leads to chronic muscle inflammation associated with muscle weakness. It is characterized by a restrictive ventilatory syndrome requiring ventilatory support under non-invasive ventilation. The
Ana Marinho +3 more
doaj +3 more sources
Anesthetic management of a hydrocephalus patient with inclusion body myositis
Inclusion body myositis (IBM) is an inflammatory muscle disease characterized by slowly progressive muscle weakness and wasting, especially affecting proximal leg and distal arm.
Daiki Takekawa +5 more
doaj +1 more source
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell +11 more
wiley +1 more source
Th1 response and systemic treg deficiency in inclusion body myositis.
ObjectiveSporadic inclusion body myositis (sIBM), the most frequent myositis in elderly patients, is characterized by the presence muscle inflammation and degeneration.
Yves Allenbach +16 more
doaj +1 more source
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt +7 more
wiley +1 more source
Inclusion Body Myositis presenting with macroglossia: A diagnostic challenge
Patients with Inclusion Body Myositis (IBM) may present with symptoms such as dysarthria and dysphagia, often before a formal diagnosis. Increased awareness and understanding of IBM among clinicians can help identify early signs, leading to timely ...
Aaron Patel, Suresh Shetty
doaj +1 more source
Abstract Objectives Hypertransaminasemia is a frequent finding in hospitalized children with common pediatric illnesses, often considered a transitory phenomenon associated with systemic inflammation/injury. This study aims to assess the prevalence and causes of incidentally detected hypertransaminasemia in children admitted to general pediatric units ...
Angelo Di Giorgio +21 more
wiley +1 more source
This cross-sectional study aimed to explore the relationships between physical disability, depression, and wellbeing in people with inclusion body myositis, a rare and progressively disabling muscle disease.
G. Nunn +5 more
doaj +1 more source
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor +5 more
wiley +1 more source

